.. Nouveaux-effets-indésirables-rapportés and .. De-gilenya®, 97 4. Conclusions sur l'évaluation du rapport bénéfice, p.97

E. Evaluation, AMM en thérapeutique Anti-Infectieuse Benoît SCHLEMMER -Hôpital Saint-Louis et

J. Richmond, The 3Rs-Past, present and future 84- 92 -Veissier I. Expérimentation animale : biologie, éthique, réglementation. Prod Anim, Scand J Lab Anim Sci, vol.27, issue.12, pp.365-375, 1999.

?. Cpmp and /. Ich, Reproductive Toxicology: Toxicity on Male Fertility International Conference of Harmonization Topic S1C " Dose selection for carcinogenicity studies of pharmaceuticals, International Conference of Harmonization Topic S5B, p.95, 2000.

J. Antic, Méthodes non-paramétriques en Pharmacocinétique et/ou Pharmacodynamie de population, Thèse : Mathématiques ? Statistiques, 2009.

J. Guillon, Place et rôle de la pharmacologie de sécurité dans le développement des médicaments. Département « Deposition Safety & Animal Research », groupe de pharmacologie, Sanofi-Aventis, 2010.

E. Guidance, Guidance sur l'investigation non-clinique du potentiel de dépendance des médicaments» 24, 2004.

R. Européen, ) relatif aux médicaments à usage pédiatrique, 2006.

?. Europa and . Synthèse-de-la, Législation de l'UE ? Médicaments à usage pédiatrique 28 Guideline on the environmental risk assessment of medicinal products for human use, 2010.

Q. Picat, . Houédé, S. Chamorey, and . Mathoulin, Pélissier -Essais cliniques de phase 0 : état de la littérature 2006 ? 2009 -4ème Conférence Francophone d'Epidémiologie Clinique, 2010.

D. Moher, Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists, Controlled Clinical Trials, vol.16, issue.1, pp.62-73, 1995.
DOI : 10.1016/0197-2456(94)00031-W

. Procédures-d-', AMM -Autorisations de mise sur le marché -Pr Philippe Lechat Directeur de l'Evaluation des Médicaments et des produits biologiques -AFSSAPS

R. Bénéfice and /. Risque, le calcul permanent ? Les Entreprises du Médicament 51. Benefit-risk methodology project, 2010.

J. Rosenhead and J. Mingers, Rational analysis for a problematic world revisited, 2001.

D. Eddy and L. Schlessinger, Validation of the Archimedes diabetes model Brandeau ML. Modeling complex medical decision problems with the Archimedes model, Diabetes Care. Annals of Internal Medicine, vol.26143, issue.114, pp.3102-10303, 2003.

R. Krishna, Model-Based Benefit???Risk Assessment: Can Archimedes Help?, Clinical Pharmacology & Therapeutics, vol.143, issue.3, pp.239-279, 2009.
DOI : 10.1016/S0009-9236(97)90160-0

W. Winston, Simulation Modeling using @RISK: Cengage Learning, 2001.

T. Koski and J. Noble, Bayesian Networks: An Introduction, 2009.
DOI : 10.1002/9780470684023

L. Savage, The Foundations of Statistical Inference., Biometrika, vol.51, issue.1/2, 1962.
DOI : 10.2307/2334244

R. Clemen and T. Reilly, Making Hard Decisions with Decision Tools Suite: Update: Brooks/Cole, 2005.

J. Beckmann, Basic Aspects of Risk-Benefit Analysis, Seminars in Thrombosis and Hemostasis, vol.25, issue.01, pp.89-95, 1999.
DOI : 10.1055/s-2007-996430

L. Lynd, M. Najafzadeh, L. Colley, M. Byrne, A. Willan et al., Using the inremental net benefit framework for quantittive benefit-risk analysis in regulatory decision-making--A case study of alosetron in irritable bowel syndrome, Value in Health, 2009.

F. Sonnenberg and J. Beck, Markov Models in Medical Decision Making, Medical Decision Making, vol.4, issue.4, pp.322-360, 1993.
DOI : 10.1177/0272989X9301300215

V. Belton and T. Stewart, Multiple Criteria Decision Analysis: An Integrated Approach, 2001.
DOI : 10.1007/978-1-4615-1495-4

J. Nunnally and I. Bernstein, Psychometric Theory, 1978.

I. Edwards, B. Wilholm, and C. Martinez, Concepts in Risk-Benefit Assessment A Simple Merit Analysis of a Medicine?, Drug Safety, vol.15, issue.1, pp.1-7, 1996.
DOI : 10.2165/00002018-199615010-00001

G. Jr, . Lp, A. Towse, and B. Bresnahan, Assessing a strucured, quantitative health outcomes approach to drug risk-benefit analysis, Health Affairs, vol.26, issue.3, pp.684-95, 2007.

R. Gelber, B. Cole, S. Gelber, and A. G. , Comparing Treatments Using Quality- Adjusted Survival: The Q-Twist Method. The American Statistician, pp.161-170, 1995.

W. Holden, Benefit-Risk Analysis, Drug Safety, vol.13, issue.4, pp.853-62, 2003.
DOI : 10.2165/00002018-200326120-00002

F. Johnson, Measuring conjoint stated preferences for pharmaceuticals: A brief introduction. Research Triangle Park, NC: RTI Health Solutions, 2006.

C. Au and . De-dijon, Le point sur la sclérose en plaques -du diagnostic aux récentes découvertes, 2009.

L. Biogen, Comprendre la sclérose en plaque Disponible sur : <http://www.biogenidec.fr/sep-sclerose-en-plaques/comprendre_definition.php> 79, Bulletin Fondation Charcot ? Numéro, pp.30-2011

A. Handel and A. Williamson, An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis, PLoS ONE, vol.14, issue.Pt 5, p.12496, 2010.
DOI : 10.1371/journal.pone.0012496.s001

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1452, 1983.
DOI : 10.1212/WNL.33.11.1444

S. Jean-daniel, Académie nationale de médecine, (article)] (33 ref.) Académie nationale de médecine, pp.699-710, 1947.

J. Chun and H. , Hartung -Clin Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis -Neuropharmacol. Author manuscript; available in PMC, Clin Neuropharmacol, 2010.

J. Cohen, F. Barkhof, G. Comi, G. Izquierdo, B. Khatri et al., -Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS -J Neurol, pp.2023-2055, 2013.

A. Thomson-core-medical, . Publishing, and . Knutsford, UK -Emerging therapy review FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value